Article by Assoc. Prof. Dr. Yaowanut Kongdan
A New Dimension in Treatment! A study in The New England Journal of Medicine published the latest clinical results demonstrating the success of the immunotherapy drug pembrolizumab in combination with chemotherapy in high-risk early-stage triple-negative breast cancer (TNBC) patients.
Key highlights from the study
Comparative study between
Pembrolizumab group: Received in combination with chemotherapy before surgery and continued after surgery.
Control group (Placebo): received chemotherapy plus a placebo.
This combination treatment has shown impressive results, significantly improving survival and reducing the risk of disease recurrence. Studies have shown that patients who received pembrolizumab in combination with chemotherapy before and after surgery had significantly better outcomes than those who received chemotherapy alone.
New treatment approaches
This treatment consists of two important steps:
Neoadjuvant therapy to reduce the size of the tumor
Adjuvant therapy after surgery to prevent disease recurrence
New hope for patients
This innovative treatment opens a new dimension for TNBC patients, particularly those at high risk who have previously had limited treatment options. This discovery could set a new standard for treating this type of breast cancer.
Advice for patients
If you or someone close to you has been diagnosed with triple negative breast cancer, you should consult a specialist as soon as possible to consider the most appropriate treatment approach, especially this new and highly effective treatment.
Comments